Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xingbaiji Formula is a traditional Chinese medicine (TCM) herbal compound administered as an adjunctive therapy in combination with chemotherapy and the PD-1 inhibitor sintilimab for the first-line treatment of metastatic, multi-target mutation-negative non-small cell lung cancer (NSCLC). The formula is provided as two granule preparations taken orally alongside standard chemotherapy regimens. While the precise herbal composition and mechanism of action are not fully detailed in available clinical trial protocols, TCM formulas like Xingbaiji are generally believed to modulate immune function, reduce toxicity from chemotherapy, and improve patient quality of life. Clinical studies are ongoing to evaluate its efficacy and safety when combined with modern oncologic therapies[5][1][2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xingbaiji Formula.